Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations
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The IKZF1 gene encodes the Ikaros transcription factor, a key regulator of lymphocyte differentiation.
1 IKZF1 is mutated in 20-30% of B-cell acute lymphoblastic leukemia (B-ALL) mostly by genomic deletions. [2] [3] [4] Several reports have shown that IKZF1 deletions are associated with an adverse prognosis, especially in pediatric patients. [3] [4] [5] [6] [7] [8] [9] [10] Ikaros mutations fall mainly into three types: (a) deletions of exons 4-7 (D4-7), which lead to the synthesis of the Ikaros-6 (Ik6) dominant-negative isoform; (b) deletions of exons 2-7 (D2-7), which delete the initiation codon and lead to haploinsufficiency; and (c) larger deletions of various sizes, which affect the coding exons (referred to below as 'complete' deletions). Thus, IKZF1 mutations have until now been separated into dominant-negative and haploinsufficient groups. Here we report that about 20% of B-ALL patients with IKZF1 mutations present two distinct deletions. These deletions are biallelic, leading to a complete loss of Ikaros function, or biclonal, marking distinct clones within the leukemia. These results highlight a more complex picture of IKZF1 loss of function in B-ALL than thought previously.
IKZF1 status was analyzed in bone marrow samples from 139 B-ALL patients (46 adult and 93 pediatric), followed at the OncoHematology Departments of the Strasbourg and Mulhouse Hospitals from 2000 (Supplementary Table S1 ). To identify D2-7 or complete deletions, we quantified exon 2 and 8 DNA levels by quantitative PCR (qPCR) (Figure 1a) . The D4-7 deletions were identified by PCR analysis with primers on each side of the conserved breakpoint 3 (Supplementary Figure S1) . The copy number of all IKZF1 exons was also assessed by multiplex ligation Accepted article preview online 18 July 2012; advance online publication, 7 August 2012 Letters to the editor PCR amplification (MLPA) 11 for 67 samples, including most of those for which IKZF1 deletions were identified using the above PCR-based methods. Five samples were analyzed by high-density comparative genomic hybridization (CGH)-array, with a dedicated array covering the IKZF1 locus and its surroundings (Agilent, Santa Clara, CA, USA). The presence of full-length or Ik6 mRNA was analyzed by reverse-transcription PCR (RT-PCR), with primers from exons 2 and 8. Finally, the size, abundance and localization of Ikaros proteins were analyzed by western blot (WB; 11 samples) and immunofluorescence (13 samples). IKZF1 status was defined from the combined results of these analyses (Supplementary Table S1 ).
We identified 60 IKZF1 mutant alleles in 49 patients (24 adult and 25 pediatric patients; see Supplementary Table S1 , and Figure 1b for the distribution of the mutations in the affected patients). Four patterns of mutations were seen: dominantnegative, haploinsufficient, biallelic or biclonal.
Fifteen of the patients exhibited the D4-7 deletion, which correlated with the presence of Ik6 transcripts (all 15 cases) and protein (all 3 cases analyzed by WB). An additional patient (patient L1867) did not show a D4-7 deletion by MLPA or PCR but expressed Ik6 mRNA and protein (Figures 1c and f (red box)). Further, PCR analysis revealed a larger D4-7 deletion with nonconventional breakpoints (Supplementary Figure S2) . In Ik6-expressing leukemic cells, Ikaros proteins were detected mainly in the cytoplasm (Figure 1g ). Furthermore, Ik6 levels were higher than those of wild type (WT) Ikaros isoforms (Figure 1f ), suggesting that Ik6 might be more stable or better translated.
In all, 44 of the 60 identified mutations were predicted to lead to loss-of-function alleles (collectively defined as null alleles). They included 14 D2-7 deletions, 26 complete deletions (including 10 cases of chromosome 7p rearrangements or deletions), 2 deletions of exon 8 (detected as isolated exon 8 deletions by qPCR and in one case as a D4-8 deletion by MLPA) and 2 deletions of exon 1 and upstream sequences (detected by CGH-array analysis and as a specific loss of exon 1 by MLPA in one case, Figure 1d and Supplementary Table S1 ). Both cases of the 5 0 deletions removed the IKZF1 promoter and were predicted to lead to loss of transcription from the affected alleles. The presence of a single null allele was the only IKZF1 abnormality detected in 27 of the 49 patients with IKZF1 deletions. These leukemias were therefore haploinsufficient for IKZF1. Indeed, these patients expressed Ik1/ Ik2 mRNA and protein, suggesting that the remaining allele was functional ( Figures 1c, f and g ). Immunofluorescence analysis clearly showed less nuclear Ikaros when compared with cases expressing WT Ikaros, confirming that IKZF1 haploinsufficiency led to reduced Ikaros proteins. Surprisingly, 11 patients exhibited two distinct IKZF1 mutations. Six of them had both a D2-7 and a complete deletion, revealed as a near total loss of exon 2 and a B50% loss of exon 8 by qPCR. These leukemias were therefore predicted to be null for Ikaros. Patient L9142 is represented in Figure 1a . This patient was also analyzed by CGH-array and MLPA, which confirmed the loss of exon 2-7 at both alleles (Figure 1d ; compare L9142 with L9188). Accordingly, no Ikaros proteins were detected in these leukemias by WB or immunofluorescence (Figures 1f and g ). Patient L1867, which had a non-canonical D4-7 deletion (see above), also exhibited a D2-7 deletion. This patient lacked WT Ikaros mRNA (Figure 1c , red box) and protein (Figure 1f) , strongly suggesting that these mutations were present in the same cells. Thus, seven patients showed clear biallelic IKZF1 mutations. The repeated occurrence of biallelic mutations suggests that, in some patients, the loss of the second IKZF1 allele provides a selective oncogenic advantage to leukemic cells that had already lost one allele.
Four patients displayed a D4-7 deletion and a haploinsufficient mutation (Figure 1b) , but still exhibited WT mRNA and protein ( Figure 1c , blue boxes; patient H2267 in Figure 1f , and data not shown). The presence of these WT products might reflect the presence of contaminating non-leukemic cells, and/or that the IKZF1 mutations are biclonal. In addition, patient H2267 had a large 5 0 deletion and a D4-7 deletion as revealed by CGH-array analysis (Figure 1d ), but the decrease in copy number of the 5 0 sequences was lower than that of the exon 4-7 segment, suggesting that the 5 0 deletion affected only a portion of the cells, whereas the D4-7 deletion affected many more. Immunofluorescence analysis confirmed that the cytoplasmic Ik6 form was not detected in all cells, and that B20% of the cells exhibited low nuclear Ikaros staining (Supplementary Figure S3) . Similar results were obtained for patient L1953 by immunofluorescence (Supplementary Figure S3) . Interestingly, patient M1 had a complete deletion and a D4-7 deletion at diagnosis, but only retained the complete deletion at relapse (Figure 1e ), indicating that these mutations occurred in different clones. Our results suggest that some IKZF1 mutations occur as secondary events during leukemogenesis. A similar conclusion was reached in a study of monozygotic twins with identical Bcr-Abl fusions but discordant IKZF1 mutations. 12 The finding that IKZF1 mutations can be heterogeneous at diagnosis suggests that monitoring D4-7 deletions for minimal residual disease assessment, as suggested by several studies, 7, 13 may carry a risk of missing the resurgent clone.
We observed several interesting associations between IKZF1 mutations and clinical features. Among B-ALL subtypes, the D4-7 deletion was enriched in Phi-positive cases and haploinsufficient deletions were enriched in Phi-negative cases (Figure 2a ; P ¼ 0.0006). This was true in both adult and pediatric cases. There was no clear association between biallelic mutations and specific clinical subtypes. In pediatric B-ALL, IKZF1 mutations were The log ratio (calculated by the Feature Extraction algorithm) for each probe present in the selected genomic region is shown. (e) Discordant mutational profiles for patient M1 at diagnosis and relapse. In this patient, the monoallelic IKZF1 deletion may correspond to a chromosome 7 rearrangement/monosomy, explaining the normal ratio when normalized to the Cog5 gene (which is on chromosome 7). The bottom panels show detection of the D4-7 deletion. b2M corresponds to the control amplification of a segment of the gene encoding b2-microglobulin. Note that a similar comparison between diagnosis and relapse was not possible for the other cases with mixed D4-7 and haploinsufficient deletions, as the patients did not relapse. (f) WB analysis. The asterisk points to a likely cross-reacting non-specific polypeptide. Arrowheads point to physiologically expressed Ikaros proteins. Note that D2 deletion means D2-7 deletion. (g) Immunofluorescence analysis. The genotype of the leukemia, as deduced from DNA analyses, is indicated on the left. Note that sample H2267 is considered here as harboring a D4-7 deletion, even though it also has a minor 5 0 deletion. The lack of signal in cases with null mutations shows the specificity of the antibody for Ikaros in this assay.
associated with a more severe outcome, as previously published (Figure 2b) . 4, 5 In adult B-ALL, 21/46 patients had the t(9;22) translocation. The Phi-positive patients received an imatinibcomplemented treatment (GRAAPH protocol), whereas the Phinegative patients received a standard treatment (GRAALL03 or GRAALL05 protocol). The overall survival and progression-free survival were similar between Phi-positive and Phi-negative patients (Supplementary Figure S4) . Because most Phi-positive patients presented an IKZF1 mutation, we could not determine if the IKZF1 mutation influenced treatment outcome, as previously reported for Phi-positive patients not treated with imatinib. 3, 9 In the Phi-negative patients, there was a significant decrease in overall survival and progression-free survival of the IKZF1-mutated group versus the IKZF1-WT group (Figure 2c) . A negative influence Letters to the editor of the D4-7 deletion on the prognosis of Phi-negative adult leukemias was recently reported in the Chinese population. 9 Our data confirm this negative prognostic value and extend it to haploinsufficient and null mutations (Figure 2c, right panels) .
Given the strong association between IKZF1 mutations and a pejorative prognosis, a systematic assessment of IKZF1 status at diagnosis is considered. This will require the development of simple and accurate methods to detect IKZF1 mutations. Our study illustrates that this goal represents a major challenge, because none of the assays we used identified all of the IKZF1 anomalies. Our PCR-based strategy identified most mutations, but missed a non-canonical D4-7 deletion and two 5 0 deletions. MLPA failed to correctly detect IKZF1 mutations in eight positive cases, notably those with biallelic/biclonal mutations and D4-7 deletions. Furthermore, we did not assess point mutations, which are expected in 2-3% of B-ALL cases. [2] [3] [4] RT-PCR appears to be the best method to identify mutations that lead to Ik6 production as this assay, but not the genomic PCR assay or MLPA, could identify this anomaly in patient L1867. Our study suggests that the analysis of Ikaros protein level and localization by immunofluorescence might be an effective way to assess Ikaros status. This method allows the identification of all classes of mutations, especially those with IKZF1 haploinsufficiency, which are associated with reduced nuclear staining. Thus, the development of a standardized immunohistochemical detection assay to assess Ikaros status in B-ALL is worth considering.
In conclusion, our data highlight a complex pattern of IKZK1 mutations in B-ALL. Haploinsufficiency appears to be the dominant mode of Ikaros deficiency and affects about 60% of cases. The other cases exhibit more severe, dominant-negative or null, mutations. The presence of biallelic mutations in 15% of affected patients shows that loss of a second IKZF1 allele provides a selective advantage over haploinsufficiency in some cases. The occurrence of biclonal mutations suggests that IKZF1 deletions may be secondary events during leukemogenesis. Finally, the predominance of dn mutations in Phi-positive cases suggests that the type of the IKZF1 mutation is influenced by other genetic events in the leukemia. Further research is thus required to understand how IKZF1 mutations functionally interact with other leukemogenic mutations.
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